Excited to share my first last-author research paper in @CR_AACR where we comprehensively identify and validate resistance mechanisms to KRAS inhibitors in #PancreaticCancer.
This work was led by a fantastic medical resident @SzuAunLongMD, and two phenomenal grad students Haley Todd and @grace_goodhart. @SyedAAhmad5@ambermamparo@bryant_kl@G_AaronHobbs@UCincySurg@Julien__Dilly@cjder23
Take-home messages:
1. KRAS Q61H-mutant PDAC is genetically and pharmacologically less dependent on KRAS for survival. We think this is due to biochemical idiosyncrasies that create an increased dependence on WT RAS isoforms. This creates a susceptibility to combined EGFR inhibition in a KRAS Q61H-mutant setting in PDAC models.
2. Additional validated hits include PI3K alpha and gamma, YAP, CK2 (formerly known as casein kinase 2).
3. We also generated KRASi-resistant PDAC cell lines that underwent an EMT, had low ERK MAPK signaling (yet remained dependent on ERK MAPK signaling), and we determine that after a 30 day compound removal, resistance was largely reversible.
Support from @theNCI@AmericanCancer@PanCAN among others.
aacrjournals.org/cancerres/a…
Dr. @ABerkenblit, PanCAN's Chief Scientific and Medical Officer, shares: "A new location. Record numbers of attendees, poster presentations and talks. A buzz of energy — of hope and optimism — that I’ve never seen before at a pancreatic cancer conference. This year’s PanCAN Scientific Summit was an event to remember.
Hosted in sunny San Diego, the Summit brought together PanCAN’s Community for Progress, including research grant recipients, Scientific and Medical Advisory Board members, Industry Champions, patient research advocates, members of our Board of Directors and other special guests. Everyone in the room was there with a shared purpose — to turn science into survival.
The opening reception showcased 27 posters, representing clinical progress from Industry Champions and scientific updates from grantees and users of our SPARK health data platform. We were also delighted to invite nine travel scholars to attend the conference — graduate students and postdoctoral fellows who displayed posters of their research projects and received feedback from experts in the field. One of the happiest outcomes was the strong comradery amongst the travel scholars — trainees who are working hard to establish their own careers as pancreatic cancer researchers and now have a network of new mentors and peers to lean on for support.
As we were preparing the agenda for this year’s Scientific Summit, we knew we had to spotlight RAS — a protein mutated in more than 90% of pancreatic tumors that was considered undruggable for decades — until now. In August of this year, the first RAS-targeting drug for patients with pancreatic cancer was approved after showing a doubling of overall survival compared to chemotherapy in a recent clinical trial.
Today, there are more than 80 different RAS-targeting drugs in clinical development for treating cancer.
As we look forward to navigating this new era of treatment options for pancreatic cancer, we also took the opportunity to look back on what it took to get here. Three of the world’s leading experts on RAS biology — Drs. Dafna Bar-Sagi, Channing Der and Frank McCormick — sat down to discuss whether RAS would ever be a druggable target at a PanCAN Scientific Meeting back in 2016. Ten years later, we were able to reassemble the three of them alongside Dr. Brian Wolpin, the principal investigator for the RASolute-302 clinical trial that led to the approval of RASONQUE™ (daraxonrasib), for a robust discussion about the past, present and future of studying and targeting RAS.
The excitement was palpable as the discussion turned to how various stakeholders — scientists, clinicians, industry, patient advocates, regulatory agencies and more — are working together to incorporate RAS inhibition into the treatment of pancreatic cancer and aiming to make it even more effective."
Read more in a special edition of Dr. Berkenblit's Research Spotlight at 🔗 pcan.at/2a6a08mz.
We are pleased to announce @AndrewWaters, PhD, from @UC_Health, as a 2026 PanCAN grant recipient, made possible by generous support from PanCAN donors. 🔬
Dr. Waters will lead a research project titled “Determining the role of KSR in mediating resistance to KRAS inhibition in PDAC.” This grant is in memory of Terry Newendrop.
Read more about Dr. Waters’s project at 🔗 pcan.at/bs58394r.
Meet Dr. Andrew Waters, an Assistant Professor of Medical Surgical Oncology at the University of Cincinnati. Dr. Waters highlights his lab's research into how pancreatic cancer cells develop resistance to KRAS inhibitors: bit.ly/4eGToSE
Paradigm shifted.
Humbled and proud for my lab to be involved in the initial description of rmc-7977, the preclinical analog of Daraxonrasib.
To quote someone I highly respect, this is "the end of the beginning"
This is a true watershed moment.
Let's move the needle!
Ieri ad #ASCO2026 ho visto una sala piena di oncologi, ricercatori e operatori sanitari alzarsi in piedi per applaudire uno studio clinico sul tumore del pancreas.
Per chi non lavora in oncologia può sembrare una cosa normale.
Per chi, come me, ha passato anni a studiare i tumori guidati da KRAS, è stato un momento che difficilmente dimenticherò.
🧵
Last week Grace and Haley attended the 2026 Julie M. Brown and Christina Gianoplus Symposium on RAS in GI Cancers in Wrightsville Beach, NC.
We are so proud of Grace and Haley for their participation and representation at the symposium. 👏🔬🎓
This April, we got a drug revolutionary in 3 ways: daraxonrasib roughly doubles survival in metastatic pancreatic cancer, cracked RAS, a protein deemed untreatable for decades & pioneered a drug class called molecular glues. Read more in my piece @WorksInProgMagworksinprogress.news/p/pancr…
- Pancreatic cancer is a particularly tough cancer.
- It's diagnosed late in its progression and it coats itself with tissue that block the immune system from attacking it. This makes immunotherapies, which have been revolutionary in other metastatic cancers (e.g. melanoma) ineffective against it.
- 90% of pancreatic cancer have one mutated protein: RAS. This should make it easily targetable. But ... not so quick! - RAS has a property that has made it "undruggable" for decades: it largely lacks the pockets or grooves that most drugs depend on to bind and act upon their target.
- Molecular glues sidestep the problem entirely. Instead of binding a pocket, daraxonrasib forces two proteins together — locking RAS in its inactive state by wedging a third protein in the way.
- The result: median survival of 13.2 months vs ~6 on standard chemo. Not a cure, but a genuine doubling, delivered as a daily pill.
- The implications go far beyond pancreatic cancer. RAS is mutated in lung, colorectal, and many other cancers. Molecular glues are now being developed against multiple other "undruggable" targets. The assumption that certain proteins are simply beyond reach has turned out, repeatedly, to be wrong.
- The bad news is that most patients eventually develop resistance mutations that vary from patient to patient. In order to deliver a real cure, we need to rethink our regulatory system and make small-n, early stage bespoke trials much easier to run.
Full circle moment! Super proud to be a Project Purple runner and grantee! Our lab at @uofcincycancer is pushing research forward and move the needle! Ran my first @RunFlyingPig half-marathon in support of @Run4Purple!
At the University of Cincinnati College of Medicine, we’re getting a behind-the-scenes look at the critical pancreatic cancer research we recently funded. This investment, totaling $375K, supports a KRAS study led by Dr. Andrew M. Waters: projectpurple.org/cincinnati…
At the University of Cincinnati College of Medicine, we’re getting a behind-the-scenes look at the critical pancreatic cancer research we recently funded. This investment, totaling $375K, supports a KRAS study led by Dr. Andrew M. Waters: projectpurple.org/cincinnati…
Our Founder and CEO, Dino Verrelli, has exciting research investment updates regarding grants focused on early detection and the KRAS mutation. With the oncology community entering a transformative era, Project Purple is proud to be at the forefront, driving progress.💜